GLOBAL REACH. HUMAN TOUCH.
From our founding, Biorasi has been driven by one mission: to bring critical therapies to patients through collaboration, clarity, and commitment.
WHO WE ARE
Over more than 20 years, that philosophy has shaped who we are: a midsize, full-service CRO trusted by sponsors worldwide for our ability to unite scientific excellence, operational discipline, and genuine partnership. Under one solution.

MILESTONES THAT DEFINE US
- 200+ Trials
- 48 Countries
- 2 FDA Approvals in 2025
Behind every number is a therapy that reached people –including rare disease treatments that might not have made it without intervention.
HOW WE WORK
CONNECTED TEAMS, CLEAR DECISIONS
Our leadership stays engaged throughout the trial — making decisions alongside your team, not above it. This ensures faster answers, better alignment, and stakeholders that stay engaged from first contact to final close-out.
CULTURE OF ACCOUNTABILITY
Our people take personal ownership of every trial. That means anticipating challenges, addressing them head-on, and staying accountable to the sponsors, investigators, and patients we serve.
THERAPEUTIC FOCUS, GLOBAL PERSPECTIVE
We operate across five core therapeutic areas — Dermatology, Oncology, Neurology, Nephrology, and Cell Therapy — with teams that understand the nuances of each field. Combined with a global site network in 48 countries, we execute trials wherever patients are.

WHAT DRIVES US
At Biorasi, we believe every trial is more than a project — it’s a responsibility. The work we do impacts real lives, and that’s why we approach every partnership with focus, humility, and determination. Our values of Reliability, Flexibility, and Accessibility aren’t marketing jargon — they’re the principles we follow daily to deliver meaningful results.
FROM OUR PARTNERS
News
Biorasi India is your guide to successful APAC trials
News
Biorasi Welcomes Veteran CRO Industry Leader Dr. Joseph Avellone to Board of Directors
News
Biorasi Welcomes Nephrologist
Dr. Jamie Dwyer to Scientific Advisory Board
News